Abstract: Post-traumatic stress disorder (PTSD) is an often debilitating disease with a lifetime prevalence rate between 5–8%. In war veterans, these numbers are even higher, reaching approximately 10% to 25%. Although most patients benefit from the use of medications and psychotherapy, approximately 20% to 30% do not have an adequate response to conventional treatments. Neuromodulation strategies have been investigated for various psychiatric disorders with promising results, and may represent an important treatment option for individuals with difficult-to-treat forms of PTSD. We review the relevant neurocircuitry and preclinical stimulation studies in models of fear and anxiety, as well as clinical data on the use of transcranial direct current stimulation (tDCS), repetitive transcranial magnetic stimulation (rTMS), and deep brain stimulation (DBS) for the treatment of PTSD.

Keywords: deep brain stimulation; fear extinction; post-traumatic stress disorder; transcranial direct current stimulation; transcranial magnetic stimulation

1. Introduction

Post-traumatic stress disorder (PTSD) is an often devastating disease with prevalence between 5–8% [1–4]. In war veterans, these numbers are even higher, reaching approximately 10–25% [5,6]. It occurs more frequently when the trauma involves certain features, including serious injury, threat of death, or threat to physical integrity. Other types of trauma associated with the development of PTSD include sexual assault, serious accidents, and the unexpected death of a loved one. The symptoms of PTSD are complex, and involve intrusive thoughts, re-experiencing the events, the persistent avoidance of stimuli associated with the trauma, alterations in mood, and persistent symptoms of hyperarousal. Feelings of fear and helplessness are also associated with PTSD. In addition to suffering, PTSD affects multiple dimensions of the patients’ lives, posing substantial stress to family members and caregivers. Due to loss of productivity and increased health costs, the economic burden associated with PTSD may be substantial.
The most common treatment strategy for PTSD involves the use of psychotherapy and/or medications. The former includes cognitive behavioral therapy and exposure therapy (e.g., trauma-focused cognitive behavioral therapy, eye movement desensitization and reprocessing, and prolonged exposure) [7–11]. Antidepressants, such as selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are considered first-line medications [11]. Of all the individuals treated with these regimens, up to 20% will relapse within six months [12]. For these patients, alternative pharmacotherapies include the use of second or third-line agents (e.g., mirtazapine, aripiprazole, carbamazepine) or adjunctive therapy (e.g., olanzapine, risperidone, clonidine) [11]. Ultimately, conventional therapies will be ineffective in 20–30% of patients [13]. Both non-invasive and invasive neuromodulation strategies have been proposed to treat this population, including transcranial direct current electrical stimulation (tDCS), transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS).

In this review, we describe the effects of delivering stimulation to structures involved in the neurocircuitry of fear in preclinical models, as well as clinical studies in which neuromodulation strategies have been applied to treat patients with PTSD.

2. Preclinical Models

PTSD has been commonly described as a disorder of dysfunctional fear extinction [14]. Many who experience a traumatic event experience physical symptoms and an acute posttraumatic response in the aftermath [15]. Though hypervigilance, anxiety, and avoidance of trauma-related memoranda are common, most individuals’ symptoms resolve over time. In PTSD, fear may not extinguish, and reminders can elicit dysfunctional responses long after the traumatic event [16,17].

It has been hypothesized that individuals who are predisposed to developing anxiety disorders and trauma-related disorders are more sensitive to aversive stimuli and exhibit exaggerated fear responses compared to controls [18]. Indeed, hypersensitive individuals, such as those diagnosed with PTSD, exhibit greater sympathetic responses (e.g., skin conductance and heart rate changes) to visual and imagined threat stimuli as well as to image-based conditioning [19–21].

As PTSD is a complex clinical disorder, mimicking all its aspects in preclinical models has been challenging [22,23]. In fact, the majority of the currently proposed animal models are more suited for the study of short-term trauma-induced changes in fear and anxiety [22].

A widely used rodent model involves fear conditioning/extinction. During fear conditioning, the individual learns to associate a neutral conditional stimulus (CS)—e.g., tone—with an aversive event featuring an unconditioned stimulus (US); e.g., foot shock [24]. This results in the development of conditioned fear responses (CRs) such as freezing, indicating a learned CS-US association [25]. Fear extinction involves the gradual attenuation of a previously learned CR by repeated presentations of the CS in the absence of US. Rather than deleting previously learned memories, the individual creates a new memory that serve to suppress the original fear response [26].

For the study of anxiety-like behaviors in rodent models, two paradigms have been commonly used: defensive burying and an elevated plus-maze [22,23]. Defensive burying tests the animal’s innate response to bury threatening, dangerous, or aversive objects. Treatments that reduce defensive burying are considered to be anxiolytic [22]. The elevated plus-maze consists of a plus-shape apparatus that contains two open and two enclosed arms and is elevated from the floor. Anxiolytic treatments increase the time the animal spends in the open arms [27].

3. Neurocircuitry

PTSD is a complex disorder comprised of aversive emotional learning (from one or more traumatic events) and dysfunctional memory processes that trigger fear responses without the presence of the traumatic situation [28]. Brain regions associated with PTSD are the amygdala (AMG), hippocampal formation (HPC), and prefrontal cortex (PFC) [29]. Figure 1 shows the main neurocircuitry involved in PTSD and fear conditioning/extinction.
The amygdala is an oval structure located in the temporal lobes. It is composed of distinct nuclei with particular connections and functions [30]. The amygdala may be subdivided into the central (CE) and medial nuclei (ME), intercalated cell clusters (ITC), and the basolateral amygdalar complex (BLA), which includes the lateral nucleus (LA), basal nucleus (BA), and the accessory basal nucleus [30].

The BLA receives extensive projections from subcortical [31] and primary neocortical auditory, visual, and somatosensory regions [32]. This nuclear complex is responsible for the integration of external and internal cues; thus, it is involved in the amalgamation of aversive events (US) with a non-threatening situation (CS) [33]. Information from the BLA propagates to the CE, and from there to the hypothalamus and multiple brainstem areas, including the periaqueductal grey (PAG) [34]. The PAG is involved in the expression of motor behaviors, such as freezing [35]. The hypothalamus engages autonomic responses and modulates the activity of the hypothalamic-pituitary adrenal axis [36].

Adjacent to the amygdala lies the hippocampal formation (HPC), which is a complex structure formed by the hippocampus (cornu ammonis, CA, dentate gyrus, DG) and subiculum [37,38]. The primate hippocampal formation is subdivided into anterior (ventral in rodents) and posterior (dorsal in rodents) regions [39].

The HPC is not always required for the acquisition, maintenance, and recall of conditioned fear memories. However, it plays an important role in discriminating context-dependent memories (e.g., spatiotemporal/configured representations) to restrain the overgeneralization of fear memories.
In PTSD, fear responses are overgeneralized, and occur in non-threatening contexts that are similar to the traumatic experience [28,40].

The PFC can be divided into the ventromedial prefrontal cortex (vmPFC) and dorsolateral prefrontal cortex (dlPFC). The vmPFC is responsible for the integration of sensorial, emotional, environmental, and memory cues, whereas the dlPFC controls the expression of appropriate behavioral responses [41]. In PTSD, the vmPFC appears to be hypoactive, whereas the amygdala exhibits increased activity [42]. Neuroimaging studies in military veterans [43] and sexually abused women [44] have shown decreased blood flow in the vmPFC during the presentation of trauma-related imagery, sounds, or narratives. Reduced vmPFC blood flow has also been reported in PTSD patients during emotional processing tasks [45], after trauma-reminding cues [46], and when at rest [47]. As for the hippocampus, neuroimaging data in PTSD patients have been less consistent. While some studies have shown hypoactivity of the HPC during specific trauma-related tasks [48], others have found increased activity in the left HPC during the encoding and recognition of emotional words in a declarative memory task [49]. It is believed that the dlPFC is responsible for the control and regulation of the vmPFC-AMG-HPC network activity, and that modulating the dlPFC activity may be beneficial in ameliorating key PTSD symptoms [29].

In rodents, rostral cortical regions include the medial prefrontal cortex (mPFC) and the orbital frontal cortex (OFC). Subregions of the mPFC include the anterior cingulate cortex (ACC), the prelimbic cortex (PL), and the infralimbic cortex (IL) [50,51]. While the IL is important for inhibiting fear CRs following extinction learning [52,53], the PL is primarily involved in the long-term behavioral expression of fear [53,54]. The IL appears to modulate the inhibition of fear responses by activating GABAergic ITC [54], which also receive excitatory input from the BLA, and send inhibitory efferents to the CE [55]. During normal extinction learning, IL inputs activate the ITC, thus inhibiting the CE and reducing overt fear responses (i.e., freezing) [56].

4. Stimulation in Preclinical Models

In rodent models, electrical stimulation has been delivered to various brain structures either to study its behavioral consequences or understand the role of specific regions in mechanisms of fear conditioning/extinction and anxiety. Overall, electrical stimulation through implanted electrodes (analogous to DBS) is an invasive technique that acts through complex mechanisms. Briefly, a single pulse or trains of pulses delivered at low frequencies result in the excitation of axonal pathways and cell depolarization. However, though stimulation delivered at higher frequencies (e.g., >90 or 100Hz) is still able to activate fibers, it leads to the functional inactivation of cell bodies (e.g., depolarization block) [57,58]. Under these circumstances, stimulation may modulate the activity of structures at a distance (i.e., through the activation of axonal projections), while inhibiting firing in the target region [22,59]. DBS has also been shown to modulate oscillatory brain activity, neurotransmitter release, and induce several forms of plasticity.

As introduced above, fear extinction involves the creation of new memories that permit the suppression of original fear responses (CR; e.g., freezing). Thus, memory for the conditioning stimulus still exists after extinction, but the fear response previously evoked by CS becomes suppressed [26]. In PTSD, there is a diminished executive suppression of the HPC-AMG-vmPFC neurocircuitry, resulting in the overgeneralization of fear memories and persistent fear responses [28].

Low-frequency simulation of the ventral CA1 region of the hippocampus following contextual conditioning reduced freezing during extinction [60], whereas stimulation of the dorsal CA1 or intermediate CA2 following extinction reduced plasticity and increased freezing during extinction recall tests [61,62]. Inversely, high-frequency stimulation delivered to the HPC after fear conditioning/extinction has been shown to enhance extinction and reduce freezing during recall sessions [63].

High-frequency stimulation of the ventral striatum was tested in a fear conditioning and extinction paradigm. While animals with electrodes implanted dorsal to the anterior commissure had significantly less freezing than sham controls, those implanted with ventral electrodes had the opposite response [64].
Similarly, high-frequency stimulation of the BLA was shown to reduce tone, but not contextual fear memory following conditioning [65]. Furthermore, BLA high-frequency stimulation led to anxiolytic effects in the defensive burying test and elevated plus-maze [66,67].

Several studies applied electrical stimulation to investigate the contribution of the PFC to fear conditioning and extinction. While PL stimulation time-locked to CS impaired extinction, IL stimulation had the opposite effect [52,68]. In addition, IL stimulation delivered at high frequencies for 10 minutes after various stages of conditioning and extinction reduced freezing when animals were re-exposed to the conditioning context [69–71]. In a recent study, we found that vmPFC stimulation delivered chronically (e.g., two weeks) to rodents with high levels of freezing following extinction reduced this behavioral response and improved anxiety [72].

Also tested in rodent models were rTMS and tDCS. These are non-invasive neuromodulation techniques that alter local electrical activity, neuronal firing, and may sometimes lead to changes at the circuitry level [29,73]. TMS uses focused electromagnetic pulses (trains of stimulation) and different simulation parameters to increase (high-frequency stimulation: > 1 Hz) or decrease (low-frequency stimulation: ≤ 1 Hz) cortical excitability [74]. tDCS uses constant direct current to increase or decrease cortical excitability by depolarizing (anodal tDCS) or hyperpolarizing neurons (cathodal tDCS) [74].

In a fear condition/extinction paradigm, rTMS delivered during extinction resulted in a more pronounced reduction of freezing when compared to sham stimulation [75]. It also reduced anxiety-like behavior in the elevated plus-maze and plasmatic corticosterone levels [76]. When assessing the biological mechanisms of this technique, high-frequency rTMS was shown to increase immediate early gene expression in the PFC (infralimbic region), BLA, and ventral CA1 [77], enhance glutamatergic transmission in the ACC, and influence the PTEN/Akt signaling pathway, which is involved in the regulation of memory and synaptic plasticity [78].

The use of stimulation procedures analogous to those used in humans is crucial for a better appraisal of how neuromodulation techniques restore normal fear responses. However, these are unsuited to identifying the cellular and physiological mechanisms of fear and anxiety. Optogenetics is a unique technique that permits the evaluation and manipulation of discrete aspects of physiological and disease states [79,80]. This is in contrast to the multiple changes and numerous substrates affected by clinical neuromodulation strategies. Work on the use of optogenetics to dissect mechanisms of fear and anxiety is quite extensive, and has been reviewed elsewhere [81–84].

5. Neuromodulation Studies in Clinical Practice

In clinical practice, neuromodulation treatments are being investigated for the amelioration of PTSD in patients who are resistant to conventional therapy. The non-invasive characteristic of rTMS and tDCS has placed them in the spotlight [85].

As described above, the overgeneralization of fear memories and the persistent expression of fear responses are consequences of a dysregulated neurocircuitry that mainly includes the amygdala, prefrontal regions, and hippocampus. It is believed that a treatment that is capable of augmenting the activity of prefrontal regions could be effective in ameliorating the executive control of fear responses, thus improving PTSD [73,74]. Along this line, researchers are investigating the use of rTMS and tDCS in the region of the PFC (Figure 2A,B).

Patients who have been included in rTMS studies were mostly veterans with comorbid depressive symptoms resistant to conventional treatments. The typical locus of stimulation was the dorsolateral prefrontal cortex, either unilaterally (right or left) or bilaterally. Stimulation frequencies have largely varied from 1 to 20 Hz and motor thresholds (MT) have varied from 80% to 120% [29,86–94]. All studies but one [90] have reported an improvement of PTSD symptoms (i.e., measured with the PTSD Checklist-Military Version, PCL-M; PTSD Checklist-Civilian Version, PCL-C; PTSD Checklist for DSM-5; or Clinician Administered PTSD Scale, CAPS). One episode featuring a severe adverse event (tonic-clonic generalized seizure) and a few mild adverse events (headache, dizziness) have been reported [29,87–94].
A double-blind, placebo-controlled phase II trial was performed to study the efficacy of unilateral dlPFC rTMS in ameliorating PTSD symptoms (20 Hz, two seconds of every 30 seconds, MT 80%) [88]. Ten patients received sham, and 10 received active stimulation. Although improvement was observed in both groups, patients receiving rTMS had a greater amelioration of symptoms [88].

Another randomized clinical trial investigated rTMS (1 Hz, MT 110%) applied to the right dlPFC prior to cognitive processing therapy for the treatment of combat-related PTSD. A greater improvement across sessions was observed in the active rTMS group, in which benefits were sustained for up to six months [87]. In contrast to these findings, a recent randomized controlled trial found no difference in remission rates when patients receiving active versus sham TMS were compared [95]. In that study, patients were randomized to receive left prefrontal rTMS (10 Hz, 120% motor threshold) or sham treatment. Of the 164 patients included, 81 received active left prefrontal rTMS, and 83 received sham rTMS. A primary analysis of remission (Hamilton Rating Scale for Depression score ≤ 10) revealed no significant differences between groups (40.7% in the active group, and 37.4% in sham-treated patients). PTSD symptoms in both groups were also similar [95].

tDCS studies in PTSD have largely focused on delivering stimulation along with psychotherapy, in order to potentially boost the effects of psychological interventions. A pilot study that associated prefrontal cortex tDCS (anode AF3, cathode M1) with computerized memory training showed improvements in working memory and PTSD symptoms in four veterans [96]. In a different study, the effects of tDCS (anode AF3, cathode P08) on extinction learning and consolidation were tested in 28 veterans after fear conditioning [80]. Using skin conductance as the dependent measure, results indicated that tDCS improved extinction recall and enhanced the efficacy of psychotherapy. The only randomized controlled trial using tDCS for PTSD was designed to test whether tDCS could improve extinction recall. Twelve veterans were evaluated in a virtual reality paradigm (combat-related) associated with tDCS (anode over AF3; cathode over P08) or sham stimulation. Patients were stable on other treatments prior to and during the study. Using normalized skin conductance reactivity and the PTSD Checklist for DSM-5 (PCL-5) scale as the main outcome measures, the authors found a significant reduction in arousal and the severity of PTSD symptoms [97].

In contrast to non-invasive modalities, DBS involves the administration of electrical current through electrodes implanted in the brain parenchyma (Figure 2C). Although a surgical procedure is required for system implantation, the technique is considered to be safe [98], and its results are often long-lasting [99]. To date, one PTSD patient treated with BLA DBS has been reported [100]. Eight months after surgery, he had an improvement in CAPS scores of approximately 40%. Overall,
the procedure was found to be safe, with no seizures or after-discharges being recorded during electrophysiology analyses.

6. Conclusions

There are currently no optimal treatment alternatives for patients with PTSD that are deemed to be refractory to medications and psychotherapy. Neuromodulation strategies have been successfully used in depression and obsessive compulsive disorder, and are currently being investigated for this population. With a well-characterized neurocircuitry, research into treatment alternatives for PTSD may lend itself well to direct-to-brain, neuroanatomically-guided neuromodulation strategies. Given the profound burden of this illness, it is anticipated that a higher number of studies will be published in the future evaluating the therapeutic effects of rTMS, tDCS, and DBS in the management of treatment-resistant PTSD.

Author Contributions: All of the authors either wrote parts of the text or provided insights on the manuscript.

Funding: This work was supported in part with funds from the National Institutes of Health (1R21MH110846-01), Veterans Affairs Canada and the Harquail Centre for Neuromodulation.

Conflicts of Interest: The authors have no conflict of interest related to this work.

References

1. Breslau, N.; Davis, G.C.; Andreski, P.; Peterson, E. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch. Gen. Psychiatry 1991, 48, 216–222. [CrossRef] [PubMed]
2. Breslau, N.; Kessler, R.C.; Chilcoat, H.D.; Schultz, L.R.; Davis, G.C.; Andreski, P. Trauma and posttraumatic stress disorder in the community: The 1996 Detroit Area Survey of Trauma. Arch. Gen. Psychiatry 1998, 55, 626–632. [CrossRef]
3. Fairbank, J.A.; Ebert, L.; Costello, E.J. Epidemiology of traumatic events and post-traumatic stress disorder. In Post Traumatic Stress Disorder: Diagnosis, Management and Treatment; Nutt, D.; Davidson, J.R.T.; Zohar, J., Eds.; Martin Dunitz Ltd.: London, UK, 2000.
4. Kessler, R.C.; Sonnega, A.; Bromet, E.; Hughes, M.; Nelson, C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 1995, 52, 1048–1060. [CrossRef]
5. Trivedi, R.B.; Post, E.P.; Sun, H.; Pomerantz, A.; Saxon, A.J.; Piette, J.D.; Maynard, C.; Arnow, B.; Curtis, I.; Fihn, S.D.; et al. Prevalence, comorbidity, and prognosis of mental health among US veterans. Am. J. Public Health 2015, 105, 2564–2569. [CrossRef]
6. Fulton, J.J.; Calhoun, P.S.; Wagner, H.R.; Schry, A.R.; Hair, L.P.; Feeling, N.; Elbogen, E.; Beckham, J.C. The prevalence of posttraumatic stress disorder in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans: A meta-analysis. J. Anxiety Disord 2015, 31, 98–107. [CrossRef] [PubMed]
7. Stewart, C.L.; Wrobel, T.A. Evaluation of the efficacy of pharmacotherapy and psychotherapy in treatment of combat-related post-traumatic stress disorder: A meta-analytic review of outcome studies. Mil. Med. 2009, 174, 460–469. [CrossRef] [PubMed]
8. Powers, M.B.; Halpern, J.M.; Ferenschak, M.P.; Gillihan, S.J.; Foa, E.B. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin. Psychol Rev. 2010, 30, 635–641. [CrossRef]
9. Bradley, R.; Greene, J.; Russ, E.; Dutra, L.; Western, D. A multidimensional meta-analysis of psychotherapy for PTSD. Am. J. Psychiatry 2005, 162, 214–227. [CrossRef]
10. Bisson, J.I.; Ehlers, A.; Matthews, R.; Pilling, S.; Richards, D.; Turner, S. Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br. J. Psychiatry 2007, 190, 97–104. [CrossRef]
11. Katzman, M.A.; Bleau, P.; Blier, P.; Chokka, P.; Kjernisted, K.; Van Ameringen, M.; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University; Antony, M.M.; Bouchard, S.; Brunet, A.; et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014, 14 (Suppl. 1), S1. [CrossRef]
Brain Sci. 2019, 9, 45

12. Davidson, J.R.; Connor, K.M.; Hertzberg, M.A.; Weisler, R.H.; Wilson, W.H.; Payne, V.M. Maintenance therapy with fluoxetine in posttraumatic stress disorder: A placebo-controlled discontinuation study. *J. Clin. Psychopharmacol.* 2005, 25, 166–169. [CrossRef] [PubMed]

13. Murphy, D.; Smith, K.V. Treatment efficacy for veterans with posttraumatic stress disorder: Latent class trajectories of treatment response and their predictors. *J. Trauma Stress* 2018, 31, 753–763. [CrossRef]

14. VanElzakker, M.B.; Dahlgren, M.K.; Davis, F.C.; Dubois, S.; Shin, L.M. From Pavlov to PTSD: The extinction of conditioned fear in rodents, humans, and anxiety disorders. *Neuropsychol. Learn. Mem.* 2014, 113, 3–18. [CrossRef] [PubMed]

15. Bonanno, G.A. Loss, trauma, and human resilience: Have we underestimated the human capacity to thrive after extremely aversive events? *Am. Psychol.* 2004, 59, 20–28. [CrossRef] [PubMed]

16. Van Minnen, A.; Wessel, I.; Dijkstra, T.; Roelofs, K. Changes in PTSD patients’ narratives during prolonged exposure therapy: A replication and extension. *J. Trauma Stress* 2002, 15, 255–258. [CrossRef]

17. Foa, E.B. Psychosocial treatment of posttraumatic stress disorder. *J. Clin. Psychiatry* 2000, 61, 43–48; discussion 49–51. [CrossRef] [PubMed]

18. Eysenck, H.J. The conditioning model of neurosis. *Behav. Brain Sci.* 1979, 2, 155–199. [CrossRef]

19. Blechert, J.; Michael, T.; Friends, N.; Margraf, J.; Wilhelm, F.H. Fear conditioning in posttraumatic stress disorder: Evidence for delayed extinction of autonomic, experiential, and behavioural responses. *Behav. Res. Ther.* 2007, 45, 2019–2033. [CrossRef]

20. Orr, S.P.; Metzger, L.J.; Lasko, N.B.; Macklin, M.L.; Peri, T.; Pitman, R.K. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. *J. Abnorm. Psychol.* 2000, 109, 290–298. [CrossRef]

21. Pitman, R.K.; Orr, S.P. Test of the conditioning model of neurosis: Differential aversive conditioning of angry and neutral facial expressions in anxiety disorder patients. *J. Abnorm. Psychol.* 1986, 95, 208–213. [CrossRef]

22. Reznikov, R.; Binko, M.; Nobrega, J.N.; Hamani, C. Towards a better preclinical model of PTSD: Characterizing animals with weak extinction, maladaptive stress responses and low plasma corticosterone. *J. Psychiatr. Res.* 2015, 61, 158–165. [CrossRef] [PubMed]

23. Rodgers, R.J.; Dalvi, A. Anxiety, defence and the elevated plus-maze. *Neurosci. Biobehav. Rev.* 1997, 21, 801–810. [CrossRef]

24. Myers, K.M.; Davis, M. Mechanisms of fear extinction. *Mol. Psychiatry* 2007, 12, 120–150. [CrossRef] [PubMed]

25. Romanski, L.M.; Clugnet, M.C.; Bordi, F.; LeDoux, J.E. Somatosensory and auditory convergence in the lateral nucleus of the amygdala. *Behav. Neurosci.* 1993, 107, 444–450. [CrossRef] [PubMed]

26. Johnson, L.R.; McGuire, J.; Lazarus, R.; Palmer, A.A. Pavlovian fear memory circuits and phenotype models of PTSD. *Neuropsychopharmacology* 2012, 62, 638–646. [CrossRef] [PubMed]

27. LeDoux, J.E.; Iwata, J.; Cicchetti, P.; Reis, D.J. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. *J. Neurosci.* 1988, 8, 2517–2529. [CrossRef] [PubMed]
35. Assareh, N.; Sarrami, M.; Carrive, P.; McNally, G.P. The organization of defensive behavior elicited by optogenetic excitation of rat lateral or ventrolateral periaqueductal gray. *Behav. Neurosci.* **2016**, *130*, 406–414. [CrossRef] [PubMed]

36. Hsu, D.T.; Chen, F.L.; Takahashi, L.K.; Kalin, N.H. Rapid stress-induced elevations in corticotropin-releasing hormone mRNA in rat central amygdala nucleus and hypothalamic paraventricular nucleus: An in situ hybridization analysis. *Brain Res.* **1998**, *788*, 305–310. [CrossRef]

37. Dekeyzer, S.; De Kock, I.; Nikoukashman, O.; Vanden Bossche, S.; Van Eetvelde, R.; De Groote, J.; Acou, M.; Wiesmann, M.; Deblaere, K.; Achten, E. “Unforgettable”—a pictorial essay on anatomy and pathology of the hippocampus. *Insights Imaging* **2017**, *8*, 199–212. [CrossRef] [PubMed]

38. Giap, B.T.; Jong, C.N.; Ricker, J.H.; Cullen, N.K.; Zafonte, R.D. The hippocampus: Anatomy, pathophysiology, and regenerative capacity. *J. Head Trauma Rehabil.* **2000**, *15*, 875–894. [CrossRef]

39. Fanselow, M.S.; Dong, H.W. Are the dorsal and ventral hippocampus functionally distinct structures? *Neuron* **2010**, *65*, 7–19. [CrossRef]

40. Maren, S.; Aharonov, G.; Fanselow, M.S. Neurotoxic lesions of the dorsal hippocampus and Pavlovian fear conditioning in rats. *Behav. Brain Res.* **1997**, *88*, 261–274. [CrossRef]

41. Wood, J.N.; Grafman, J. Human prefrontal cortex: Processing and representational perspectives. *Nat. Rev. Neurosci.* **2003**, *4*, 139–147. [CrossRef]

42. Diekhof, E.K.; Geier, K.; Falkai, P.; Gruber, O. Fear is only as deep as the mind allows: A coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. *Neuroimage* **2011**, *58*, 275–285. [CrossRef] [PubMed]

43. Britton, J.C.; Phan, K.L.; Taylor, S.F.; Fig, L.M.; Liberzon, I. Corticolimbic blood flow in posttraumatic stress disorder during script-driven imagery. *Biol. Psychiatry* **2005**, *57*, 832–840. [CrossRef] [PubMed]

44. Bremner, J.D.; Narayan, M.; Staib, L.H.; Southwick, S.M.; McGlashan, T.; Charney, D.S. Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. *Am. J. Psychiatry* **1999**, *156*, 1787–1795. [PubMed]

45. Shin, L.M.; Wright, C.I.; Cannistraro, P.A.; Wedig, M.M.; McMullin, K.; Marits, B.; Macklin, M.L.; Lasko, N.B.; Cavanagh, S.R.; Krangel, T.S.; et al. A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. *Arch. Gen. Psychiatry* **2005**, *62*, 273–281. [CrossRef] [PubMed]

46. Shin, L.M.; Orr, S.P.; Carson, M.A.; Rauch, S.L.; Macklin, M.L.; Lasko, N.B.; Peters, P.M.; Metzger, L.J.; Dougherty, D.D.; Cannistraro, P.A.; et al. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. *Arch. Gen. Psychiatry* **2004**, *61*, 168–176. [CrossRef] [PubMed]

47. Sripada, R.K.; King, A.P.; Garfinkel, S.N.; Wang, X.; Sripada, C.S.; Welsh, R.C.; Liberzon, I. Altered resting-state amygdala functional connectivity in men with posttraumatic stress disorder. *J. Psychiatry Neurosci.* **2012**, *37*, 241–249. [CrossRef] [PubMed]

48. Carrion, V.G.; Haas, B.W.; Garrett, A.; Song, S.; Reiss, A.L. Reduced hippocampal activity in youth with posttraumatic stress symptoms: An fMRI study. *J. Pediatr. Psychol.* **2010**, *35*, 559–569. [CrossRef]

49. Thomasa, K.; Dorrrepaal, E.; Draijer, T.P.; van Balkom, A.J.; Smoor, P.L.; Smit, J.; Veltman, D.J. Increased activation of the left hippocampus region in Complex PTSD during encoding and recognition of emotional words: A pilot study. *Psychiatry Res.* **2009**, *171*, 44–53. [CrossRef]

50. Hamani, C.; Nobrega, J.N. Preclinical studies modeling deep brain stimulation for depression. *Biol. Psychiatry* **2012**, *72*, 916–923. [CrossRef] [PubMed]

51. Uylings, H.B.; Groenewegen, H.J.; Kolb, B. Do rats have a prefrontal cortex? *Behav. Brain Res.* **2003**, *146*, 3–17. [CrossRef]

52. Milad, M.R.; Quirk, G.J. Neurons in medial prefrontal cortex signal memory for fear extinction. *Nature* **2002**, *420*, 70–74. [CrossRef] [PubMed]

53. Corcoran, K.A.; Quirk, G.J. Recalling safety: Cooperative functions of the ventromedial prefrontal cortex and the hippocampus in extinction. *CNS Spectr.* **2007**, *12*, 200–206. [CrossRef] [PubMed]

54. Amano, T.; Unal, C.T.; Pare, D. Synaptic correlates of fear extinction in the amygdala. *Nat. Neurosci.* **2010**, *13*, 489–494. [CrossRef] [PubMed]

55. Royer, S.; Martina, M.; Pare, D. An inhibitory interface gates impulse traffic between the input and output stations of the amygdala. *J. Neurosci.* **1999**, *19*, 10575–10583. [CrossRef] [PubMed]
56. Likhtik, E.; Popa, D.; Apergis-Schoute, J.; Fidacaro, G.A.; Pare, D. Amygdala intercalated neurons are required for expression of fear extinction. *Nature* **2008**, *454*, 642–645. [CrossRef]

57. Ranck, J.B., Jr. Which elements are excited in electrical stimulation of mammalian central nervous system: A review. *Brain Res*. **1975**, *75*, 417–440. [CrossRef]

58. Lozano, A.M.; Dostrovsky, J.; Chen, R.; Ashby, P. Deep brain stimulation for Parkinson’s disease: Disrupting the disruption. *Lancet Neurol.* **2002**, *1*, 225–231. [CrossRef]

59. Hamani, C.; Temel, Y. Deep brain stimulation for psychiatric disease: Contributions and validity of animal models. *Sci. Transl. Med.* **2012**, *4*, 142–148. [CrossRef]

60. Cleren, C.; Tallarida, I.; Guiniec, E.L.; Janin, F.; Nachon, O.; Canini, F.; Spennato, G.; Moreau, J.L.; Garcia, R. Low-frequency stimulation of the ventral hippocampus facilitates extinction of contextual fear. *Neurobiol. Learn. Mem.* **2013**, *101*, 39–45. [CrossRef]

61. Deschaux, O.; Thevenet, A.; Spennato, G.; Arnaud, C.; Moreau, J.L.; Garcia, R. Low-frequency stimulation of the hippocampus following fear extinction impairs both restoration of rapid eye movement sleep and retrieval of extinction memory. *Neuroscience* **2010**, *170*, 92–98. [CrossRef]

62. Farinelli, M.; Deschaux, O.; Hugues, S.; Thevenet, A.; Garcia, R. Hippocampal train stimulation modulates recall of fear extinction independently of prefrontal cortex synaptic plasticity and lesions. *Learn. Mem.* **2006**, *13*, 329–334. [CrossRef] [PubMed]

63. Rodriguez-Romaguera, J.; Do Monte, F.H.; Quirk, G.J. Deep brain stimulation of the ventral striatum enhances extinction of conditioned fear. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 8764–8769. [CrossRef] [PubMed]

64. Maroun, M.; Kavushansky, A.; Holmes, A.; Wellman, C.; Motanis, H. Enhanced extinction of aversive memories by high-frequency stimulation of the rat infralimbic cortex. *PLoS ONE* **2012**, *7*, e35853. [CrossRef]

65. Zheng, X.; Deschaux, O.; Lavigne, J.; Le Guisquet, A.M.; Belzung, C.; El-Hage, W. Prefrontal high-frequency stimulation prevents sub-conditioning procedure-provoked, but not acute stress-provoked, reemergence of extinguished fear. *Neurobiol. Learn. Mem.* **2013**, *101*, 33–38. [CrossRef]

66. Reznikov, R.; Bambico, F.R.; Diwan, M.; Nachon, O.; Cleren, C.; Moreau, J.L.; Garcia, R. Prefrontal cortex deep brain stimulation improves fear and anxiety-like behavior and reduces basolateral amygdala activity in a preclinical model of posttraumatic stress disorder. *Neuropsychopharmacology* **2018**, *43*, 1099–1106. [CrossRef] [PubMed]

67. Van’t Wout, M.; Longo, S.M.; Reddy, M.K.; Philip, N.S.; Bowker, M.T.; Greenberg, B.D. Transcranial direct current stimulation may modulate extinction memory in posttraumatic stress disorder. *Brain Behav.* **2017**, *7*, e00681. [CrossRef] [PubMed]
74. Zwanzger, P.; Steinberg, C.; Rehbein, M.A.; Bröckelmann, A.K.; Dobel, C.; Zavorotnyy, M.; Domschke, K.; Junghöfer, M. Inhibitory repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex modulates early affective processing. *Neuroimage* **2014**, *101*, 193–203. [CrossRef] [PubMed]

75. Baek, K.; Chae, J.H.; Jeong, J. The effect of repetitive transcranial magnetic stimulation on fear extinction in rats. *Neuroscience* **2012**, *200*, 159–165. [CrossRef] [PubMed]

76. Wang, H.N.; Bai, Y.H.; Chen, Y.C.; Zhang, R.G.; Wang, H.H.; Zhang, Y.H.; Gan, J.L.; Peng, Z.W.; Tan, Q.R. Repetitive transcranial magnetic stimulation ameliorates anxiety-like behavior and impaired sensorimotor gating in a rat model of post-traumatic stress disorder. *PLoS ONE* **2015**, *10*, e0117189. [CrossRef] [PubMed]

77. Legrand, M.; Troubat, R.; Brizard, B.; Le Guisquet, A.M.; Belzung, C.; El-Hage, W. Prefrontal cortex rTMS reverses behavioral impairments and differentially activates c-Fos in a mouse model of post-traumatic stress disorder. *Brain Stimul.* **2019**, *12*, 87–95. [CrossRef] [PubMed]

78. Liu, G.; Feng, D.; Wang, J.; Zhang, H.; Peng, Z.; Cai, M.; Yang, J.; Zhang, R.; Wang, H.; Wu, S.; et al. rTMS ameliorates PTSD symptoms in rats by enhancing glutamate transmission and synaptic plasticity in the ACC via the PTEN/Akt signalling pathway. *Mol. Neurobiol.* **2018**, *55*, 3946–3958. [CrossRef]

79. Sparta, D.R.; Jennings, J.H.; Ung, R.L.; Stuber, G.D. Optogenetic strategies to investigate neural circuitry engaged by stress. *Behav. Brain Res.* **2013**, *255*, 19–25. [CrossRef]

80. Sparta, D.R.; Smithuis, J.; Stamatakis, A.M.; Jennings, J.H.; Kantak, P.A.; Ung, R.L. Stuber GDInhibition of projections from the basolateral amygdala to the entorhinal cortex disrupts the acquisition of contextual fear. *Front. Behav. Neurosci.* **2014**, *8*, 129. [CrossRef] [PubMed]

81. Tovote, P.; Fadok, J.P.; Luthi, A. Neuronal circuits for fear and anxiety. *Nat. Rev. Neurosci.* **2015**, *16*, 317–331. [CrossRef]

82. Johansen, J.P.; Wolff, S.B.; Luthi, A.; LeDoux, J.E. Controlling the elements: An optogenetic approach to understanding the neural circuits of fear. *Biol. Psychiatry* **2012**, *71*, 1053–1060. [CrossRef] [PubMed]

83. Gafford, G.M.; Ressler, K.J. Mouse models of fear-related disorders: Cell-type-specific manipulations in amygdala. *Neuroscience* **2016**, *321*, 108–120. [CrossRef] [PubMed]

84. Allsop, S.A.; Vander Weele, C.M.; Wichmann, R.; Tye, K.M. Optogenetic insights on the relationship between anxiety-related behaviors and social deficits. *Front. Behav. Neurosci.* **2014**, *8*, 241. [CrossRef] [PubMed]

85. Kozel, F.A. Clinical repetitive transcranial magnetic stimulation for posttraumatic stress disorder, generalized anxiety disorder, and bipolar disorder. *Psychiatr. Clin. North. Am.* **2018**, *41*, 433–446. [CrossRef] [PubMed]

86. Fryml, L.D.; Pelic, C.G.; Acienro, R.; Tuerk, P.; Yoder, M.; Borckardt, J.J.; Juneja, N.; Schmidt, M.; Beaver, K.L.; George, M.S. Exposure therapy and simultaneous repetitive transcranial magnetic stimulation: A controlled pilot trial for the treatment of posttraumatic stress disorder. *J. ECT* **2018**. [CrossRef] [PubMed]

87. Kozel, F.A.; Motes, M.A.; Didehbani, N.; DeLaRosa, B.; Bass, C.; Schraufnagel, C.D.; Jones, P.; Morgan, C.R.; Spence, J.S.; Kraut, M.A.; et al. Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial. *J. Affect. Disord.* **2018**, 229, 506–514. [CrossRef] [PubMed]

88. Boggio, P.S.; Rocha, M.; Oliveira, M.O.; Fecteau, S.; Cohen, R.B.; Campanhã, C.; Ferreira-Santos, E.; Meleiro, A.; Corchs, F.; Zaghi, S.; et al. Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder. *J. Clin. Psychiatry* **2010**, *71*, 992–999. [CrossRef]

89. Carpenter, L.L.; Conelea, C.; Tyrka, A.R.; Welch, E.S.; Greenberg, B.D.; Price, L.H.; Niedzwiecki, M.; Yip, A.G.; Barnes, J.; Philip, N.S. 5Hz Repetitive transcranial magnetic stimulation for posttraumatic stress disorder comorbid with major depressive disorder. *J. Affect. Disord.* **2018**, 235, 414–420. [CrossRef]

90. Fryml, L.D.; Sahlem, G.; Fox, J.; Short, E.B. The role of rTMS for patients with severe PTSD and depression. *Evid Based Ment. Health* **2018**, *21*, 39–40. [CrossRef]

91. Nam, D.H.; Pae, C.U.; Chae, J.H. Low-frequency, repetitive transcranial magnetic stimulation for the treatment of patients with posttraumatic stress disorder: A double-blind, sham-controlled study. *Clin. Psychopharmacol Neurosci.* **2013**, *11*, 96–102. [CrossRef]

92. Ozrun, T.; Akarsu, S.; Celik, C.; Bolu, A.; Ozdemir, B.; Akcay, B.D.; Ozselek, S.; Bozkurt, A.; Ozmenler, K.N. Is transcranial magnetic stimulation effective in treatment-resistant combat related posttraumatic stress disorder? *Neurosciences* **2014**, *19*, 29–32. [PubMed]
93. Philip, N.S.; Barredo, J.; van’t Wout-Frank, M.; Tyrka, A.R.; Price, L.H.; Carpenter, L.L. Network mechanisms of clinical response to transcranial magnetic stimulation in posttraumatic stress disorder and major depressive disorder. *Biol. Psychiatry* 2018, 83, 263–272. [CrossRef] [PubMed]

94. Philip, N.S.; Ridout, S.J.; Albright, S.E.; Sanchez, G.; Carpenter, L.L. 5-Hz Transcranial Magnetic Stimulation for Comorbid Posttraumatic Stress Disorder and Major Depression. *J. Trauma Stress* 2016, 29, 93–96. [CrossRef] [PubMed]

95. Yesavage, J.A.; Fairchild, J.K.; Mi, Z.; Biswas, K.; Davis-Karim, A.; Philbbs, C.S.; Forman, S.D.; Thase, M.; Williams, L.M.; Etkin, A.; et al. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial. *JAMA Psychiatry* 2018, 75, 884–893. [CrossRef] [PubMed]

96. Saunders, N.; Downham, R.; Turman, B.; Kropotov, J.; Clark, R.; Yumash, R.; Szatmary, A. Working memory training with tDCS improves behavioral and neurophysiological symptoms in pilot group with post-traumatic stress disorder (PTSD) and with poor working memory. *Neurocase* 2015, 21, 271–278. [CrossRef] [PubMed]

97. van’t Wout-Frank, M.; Shea, M.T.; Larson, V.C.; Greenberg, B.D.; Philip, N.S. Combined transcranial direct current stimulation with virtual reality exposure for posttraumatic stress disorder: Feasibility and pilot results. *Brain Stimul.* 2018. [CrossRef]

98. Hamani, C.; Lozano, A.M. Hardware-related complications of deep brain stimulation: A review of the published literature. *Stereotact. Funct. Neurosurg.* 2006, 84, 248–251. [CrossRef]

99. Awan, N.R.; Lozano, A.; Hamani, C. Deep brain stimulation: Current and future perspectives. *Neurosurg. Focus* 2009, 27, E2. [CrossRef]

100. Langevin, J.P.; Koek, R.J.; Schwartz, H.N.; Chen, J.W.Y.; Sultzter, D.L.; Mandelkern, M.A.; Kulick, A.D.; Krahl, S.E. Deep brain stimulation of the basolateral amygdala for treatment-refractory posttraumatic stress disorder. *Biol. Psychiatry* 2016, 79, e82–e84. [CrossRef]